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Abstract. The combination of platelet count to mean platelet 
volume (COP-MPV) has been recently reported as a prognostic 
indicator of oral cavity cancer and other cancer sites. The aim 
of the present study was to validate the utility of the COP-MPV 
as a prognostic indicator in all head and neck cancer (HNC) 
sites. The clinicopathological characteristics of the COP-MPV 
with HNC were also investigated. This is a retrospective 
cohort study that recruited consecutively treated patients at 
a tertiary level academic hospital. Clinicopathological char-
acteristics were recorded, including the COP-MPV scores. 
Survival was analyzed using Kaplan-Meier analysis, as well as 
multivariate Cox Proportional Hazards regression. COP-MPV 
was not associated with the survival outcome in univariate 
or multivariate analysis. In the multivariate model, tumor 
differentiation, tumor stage, nodal stage, surgical margins and 
hemoglobin were revealed to be significantly associated with 
survival. The results demonstrated that the COP-MPV is not a 
suitable prognostic factor for HNC.
Introduction
Head and neck cancers (HNC) account for a significant propor-
tion of cancers in the USA (1). HNCs are typically treated 
with surgery, radiotherapy, chemotherapy, or in combination. 
Single surgical treatment with or without radiation is the 
standard therapy for Tumor-Node-Metastases (TNM) stages I 
and II (2). On the other hand, a combination of surgery, radio-
therapy, and chemotherapy may be used for more advanced 
TNM stages (3). TNM staging is a widely used scoring 
system among prognostic factors for determining patient 
survival (1,4). Previously, several biomarkers were studied as 
serologic markers albeit low specificity and difficult clinical 
application (5). As such, there is a need for finding effective 
and clinically efficient biomarkers purposed as prognostic 
factors for HNCs (6-8).
In recent studies, platelet activation was observed to be a 
significant biological process for cancer occurrence and metas-
tasis (9). Platelet (PLT) and mean platelet volume (MPV) are 
typical measures of platelet activation (10), where high levels of 
MPV signify irregular platelet production and activation (11). It 
has also been observed that abnormal MPV levels are associ-
ated with patients with various disorders and malignant tumors. 
Building on this information, several studies have recently 
investigated the prognostic utility of the combination of PLT 
and MPV (COP-MPV). A recent study by Park et al (12) found 
that the COP-MPV was a significant prognostic indicator 
in oral cavity cancer. Additionally, the COP-MPV has been 
found to be a prognostic indicator in non-small cell lung 
cancer (NSCLC) (13), and esophageal cancer as well (14). The 
study by Park was a small sample study with only 40 patients, 
and only consisted of patients with oral cavity cancer (12). 
In this context, the goal of our study was to (a) evaluate the 
prognostic utility of the COP-MPV in a larger sample size, with 
patients of all HNC subsites and (b) to determine the clinico-
pathological characteristics associated with COP-MPV.
Materials and methods
Study design. This is a retrospective cohort study that included 
consecutively-treated patients with HNC treated at the New 
York Head & Neck Institute (NYHNI) from 2009-2016. This 
study is part of a large retrospectively managed cancer data-
base (15,16) and was approved by the Institutional Review Board 
of the Northwell Health System (IRB# 17-0280-LHH). The 
study conforms to the guidelines stupilated in the Declaration 
of Helsinki. The inclusion criteria of the study included: i) histo-
logically confirmed HNC (excluding thyroid); ii) undergoing 
curative intent surgery; iii) availability of complete clinical data 
and disease records. The exclusion criteria included: i) clinical 
evidence of pretreatment infection, other inflammatory disease 
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or comorbidity that would influence results of the platelet count; 
ii) benign disease; iii) biopsies or non‑curative intent procedures 
or palliative procedures; iv) lymphoproliferative malignancies; 
v) incomplete medical records which include absence of preop-
erative complete blood count (CBC); vi) CBC that was taken 
more than two weeks pre‑operatively; and vii) neoadjuvant 
chemotherapy or radiation therapy. Patients were screened 
with pre‑defined International Classification of Diseases (ICD) 
9/10 codes and were treated according to physician discretion 
consistent with contemporary treatment paradigms.
Variable selection and data collection. Various literature were 
reviewed for significant prognostic factors in HNC that could be 
used to generate univariate and multivariate statistical models. 
The established prognostic factors for HNC used in the data 
collection process included: age, sex, body mass index (BMI), 
alcohol history, smoking history, eastern cooperative oncology 
group (ECOG) score, and Karnofsky performance status. 
All patients were retrospectively graded based on the Adult 
Comorbidity Evaluation 27 (ACE-27) score, a validated 
comorbidity scoring system for head and neck cancer (17). 
Treatment and tumor variables were also incorporated: 
Tumor differentiation, staging (8th Edition of American Joint 
Committee on Cancer System) (18), adjuvant radiation (RT), 
adjuvant chemotherapy (CT), and surgical margin status. For 
oropharyngeal tumors, human papillomavirus (HPV) status 
was determined according to either p16 positivity via immu-
nohistochemistry, or HPV DNA detection. In addition, CBC 
markers of interest were considered as well and included: the 
hemoglobin (Hb), platelet count, mean platelet volume, and 
white blood cell count (WBC). Since a unified scoring system 
has not been developed for the COP-MPV, we utilized the 
scoring system developed in the largest dataset published on 
the COP-MPV, by Zhang et al (14). The cutoffs for platelet 
count and platelet volume were set to 212 (109/L) and 10.6 (fl) 
respectively. A score of 1 was given if one of the cutoffs were 
met, and a score of 2 was given if both cutoffs were met.
Patient records were retrieved electronically from the 
REDCap database (19). Necessary and relevant clinical informa-
tion were gathered from the patients' scanned documents. Such 
documents included clinical, pathological, or laboratory reports. 
CBC parameters were obtained from preoperative lab results.
Endpoint definition. Event-free survival (EFS) was chosen as 
the primary endpoint. We chose EFS as the primary endpoint 
as a recent study by Michiels et al (20) had shown that the EFS 
was an effective proxy for OS as the primary survival endpoint. 
EFS was defined as the date of surgery to last follow‑up or 
‘event’, depending on which date was earliest. An ‘event’ was 
defined as any progress, local or distant recurrence, or death. If 
there was no occurrence of an ‘event’ at the last follow-up, the 
patient was censored for the survival analysis.
Statistical analysis. Parametric tests such as Chi-square tests 
and t-tests were used to evaluate the differences between the 
relationship of clinicopathological features. With Kaplan-Meier 
curves (KM), EFS was estimated and log-rank tests were 
used to identify survival differences between the KM curves. 
Furthermore, Cox proportional hazards model (CPH) was 
used to determine the hazard ratio (HR) of the aforementioned 
variables. Multivariate analyses was conducted on all variables 
recorded with regards to EFS. For generating a multivariate 
CPH model, backwards variable selection was used. For the 
backwards multivariate model, variables with P>0.1 were 
removed from the model. Hazard ratios (HR) with 95% confi-
dence intervals (95% CI) with two-sided P-values are presented. 
The chosen alpha level was 0.05, and all P-values less than the 
alpha level were considered statistically significant. All statis-
tical analyses, excluding cutoff derivation, were performed 
using MedCalc for Windows, version 15.0 (MedCalc Software 
bvba, Ostend, Belgium).
Results
A total of 113 patients met the inclusion and exclusion criteria 
for this study (Table I). The most common site of tumor was the 
Oral Cavity (46%) followed by the oropharynx (18%). Of the 
oropharyngeal tumors, 15 (75%) were associated with either 
p16 or HPV DNA. In regards to tumor histology, the most 
prominent type was squamous cell carcinoma (93 patients, 
82.3%). A total of 27 (24%) patients had a COP-MPV score 
of 0, 65 (58%) of patients had score of 1, and 21 (19%) of 
patients had score of 2. With regards to the clinicopathological 
characteristics and COP-MPV score, only WBC count was 
associated with higher COP-MPV values (P=0.0036, Table I).
With regards to the survival analysis, the multivariate 
analysis of EFS revealed that age, sex, BMI, Karnofsky 
score, ACE score, tumor differentiation, Staging-N, WBC, 
platelet count, and COP MPV were not significant prognostic 
indicators (Table II). The factors associated with EFS in the 
multivariable model were higher tumor grade (HR=2.37, 
95% CI: 1.17-4.84, P=0.0171), higher tumor stage (HR=8.91, 
95% CI: 3.46-22.91, P<0.0001), higher nodal stage (pN1 
HR=3.41, 95% CI: 1.11‑10.47, P=0.0321; pN2 HR=3.30, 95% CI 
1.23-8.86, P=0.0177), positive surgical margins (HR=3.77, 
95% CI: 1.54-9.24, P=0.0037), and higher hemoglobin count 
(HR=0.62, 95% CI: 0.50-0.78, P<0.0001). COP-MPV was not 
associated with EFS in the multivariate survival analysis. To 
confirm if COP‑MPV did not have a prognostic effect, we 
performed a further Kaplan Meier analysis with a log-rank 
test. The Kaplan-Meier analysis revealed that COP-MPV was 
not associated with EFS (P=0.3723, Fig. 1).
Discussion
The COP-MPV scoring system was developed by combining 
PLT and MPV to measure platelet activation and to assess the 
prognosis of cancer patients. As such, previous studies revealed 
COP-MPV to be an ideal and effective prognostic factor for 
these type of patients (12-14). Building upon previous research 
by others, this study sought to validate the prognostic value 
of COP-MPV for all HNC subsites. The results and analyses 
of this study revealed that COP-MPV was not associated with 
our primary survival outcome, EFS. There were no significant 
differences between COP-MPV scores of 0,1 and 2 with 
regard to EFS. Additionally, COP-MPV was not associated 
with EFS in the univariate Kaplan Meier analysis either. In our 
multivariate survival analysis, we found that known factors for 
survival, namely differentiation, tumor stage, surgical margins, 
and hemoglobin were associated with EFS.
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Table I. Summary of cohort characteristics stratified by COP‑MPV.
Variable COP-MPV 0a COP-MPV 1a COP-MPV 2a P-value
Age (years) 66.48 63.23 64.048 0.6027
Sex
  Male 20 43 13 0.6444
  Female   7 22 8
BMI (kg/m2) 24.89 26.50 28.76 0.0655
History of alcohol use
  Yes 12 33 12 0.6810
  No 15 32   9
History of smoking
  Yes 13 31 12 0.7426
  No 14 34   9
ECOG score
  0 16 50 16 0.3801
  1   9 14   4
  2   2   1   1
Tumor primary location
  Nasopharynx   0   1   0 0.2692
  Oropharynx   5 13   2
  Oral cavity   8 29 15
  Larynx   4   6   0
  Salivary gland   3   7   2
  Paranasal sinus   2   5   0
  Cervical lymph node or unknown primary   2   1
  Cutaneous   3   3   0
Tumor histology
  Adenocarcinoma   1   5   0 0.6290
  Squamous cell carcinoma 21 52 20
  Adenoid cystic carcinoma   1   1   0
  Mucoepidermoid carcinoma   1   1   0
  Basal cell carcinoma   1   0   0
  Other   2   6   1
Tumor differentiation
  Unable to assess   7   5   4 0.0617
  Well differentiated   7 10   3
  Moderate differentiation 11 29 10
  Poor differentiation   2 21   4
Staging pT
  pT0   2   2   2 0.6384
  pT1 10 25   9
  pT2 11 19   6
  pT3   3 11   1
  pT4   1   8   3
Staging pN
  pN0 19 41 16 0.8009
  pN1   3 10   2
  pN2   3   7   3
  pN3   2   6   0
Adjuvant radiotherapy
  Yes 12 27   4 0.1339
  No 15 38 17
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In comparison to other studies (12-14), similar factors were 
incorporated into the analyses of the results. This included 
age, sex, tumor location, degree of differentiation, TNM stage, 
WBC, platelet count, and mean platelet volume. In this study, 
we additionally controlled for BMI, ECOG score, Karnofsky 
score, types of treatment modalities, and surgical margin status.
It should be noted that by accounting for different factors in 
analyses potential differences in significance values will arise 
and thus could also influence the determination of whether 
COP-MPV affects survival. Another key difference between 
our study and other studies is the area of interest for cancers. In 
our study various locations of cancer of the head and neck area 
were included, whereas other studies mainly focused on areas 
of higher specification or a particular type of carcinom (12‑14). 
As a result, by considering different afflicted locations it may 
explain why our significance scores were different from other 
studies.
Of note, the study by Park et al (12) found that the 
COP‑MPV was significantly associated with survival in their 
multivariate analysis. However, we believe that their results 
might be limited due to several reasons. Firstly, they had a small 
sample size of patients; secondly, their multivariate model did 
not account for important covariates such as adjuvant thera-
pies and comorbidities which would have significantly biased 
their results. Our results agree with certain aspects of their 
study; they also found that tumor stage (P=0.735) and nodal 
stage (P=1.00) were not associated with COP-MPV scores. 
Nevertheless, we believe the work by Park et al (12) is the 
Table I. Continued.
Variable COP-MPV 0a COP-MPV 1a COP-MPV 2a P-value
Adjuvant chemoradiotherapy
  Yes   6 14   2 0.4420
  No 21 51 19
Surgical margin status
  Positive   3   9   3 0.9292
  Negative 24 56 18
WBC (109/l) 6.51 7.56 9.16 0.0036b
Hemoglobin (g/dl) 13.39 13.30 6.81 0.1356
MPV (fl) 9.66 9.81 11.25 <0.0001b
Platelet Count (109/l) 178.33 249.88 275.14 <0.0001b
aContinuous variables presented as mean values and categorical variables are represented as integers; bStatistically significant at P<0.05. 
BMI, body‑mass index; ACE‑27, adult  comorbidity evaluation 27 score; ECOG, Eastern Cooperative Oncology Group score; WBC, white 
blood cell count; MPV, mean platelet volume; COP‑MPV, combination of platelet count and mean platelet volume score.
Figure 1. Kaplan Meier curve of the event-free survival of COP-MPV. Kaplan-Meier curve analysis of the event-free survival of the COP-MPV. The log-rank 
test showed no significant differences between curves (P=0.3723). COP‑MPV, combination of platelet count and mean platelet volume.
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first report of COP‑MPV for a HNC subsite. In our study, we 
analyzed patients from all HNC subsites, in a larger sample 
size than the previous study by Park et al (12).
We acknowledge several limitations in our study. Firstly, 
this is a retrospective cohort study where some elements of 
bias might be in the data. Secondly, considering that different 
types of HNCs were included, each may have their own 
prognostic characteristics. We are unable to definitely draw 
a conclusion that the COP-MPV is not effective in all HNC 
subsites. Our study has several strengths: First, this includes 
rigorous control for all prognostic covariates in our analyses; 
Secondly, the included patients had similar treatment regimens 
where all experienced curative intent surgery with or without 
adjuvant radiation or chemotherapy; Third, unlike previously 
mentioned literature, we used the latest staging system (AJCC 
8th edition) in our study, which has been shown to have 
improved prognostic discrimination between stages (18). It 
should be acknowledged that the use of older staging criteria 
by other studies might have affected their results. Most impor-
tantly, this study adds on to the literature for COP-MPV as 
this is the first comprehensive study examining the prognostic 
utility of COP-MPV in all HNC subsites.
In conclusion, we did not find COP‑MPV to be related to 
the survival endpoint EFS. However, high quality prospective 
studies should be considered and are needed to validate our 
conclusions for COP-MPV. At this time, we cannot recom-
mend the COP-MPV as a prognostic indicator in HNC.
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Table II. Multivariate Cox Regression Analysis of Event-Free 
Survival.
 Multivariate analysis
 -------------------------------------------------------------------
Variable HR 95% CI P-value
Age Nsa - -
Sex
  Male Reference
  Female Nsa - -
BMI Nsa - -
History of alcohol use Nsa - -
History of smoking Nsa - -
Overall ACE-27 score Nsa - -
ECOG score Nsa - -
Karnofsky score
  100 Reference
  90 Nsa - -
  80 Nsa - -
  ≤70 c - -
Tumor primary location Nsa - -
Tumor differentiation
  Well differentiated Reference
  Moderately 2.37 1.17-4.84 0.0171b
  differentiated
  Poorly differentiated Nsa - -
Staging pT
  pT1 Reference
  pT2 Nsa - -
  pT3 8.91 3.46-22.91 <0.0001b
  pT4 Nsa - -
Staging pN
  pN0 Reference
  pN1 3.41 1.11-10.47 0.0321b
  pN2 3.30 1.23-8.86 0.0177b
  pN3 c
Adjuvant radiotherapy Nsa - -
Adjuvant Nsa - -
chemoradiotherapy
Surgical margin status 3.77 1.54-9.24 0.0037b
WBC Nsa - -
Hemoglobin 0.62 0.50-0.78 <0.0001b
MPV 2.16 0.95-4.92 0.0659
Platelet count Nsa - -
COP-MPV
  0 Reference
  1 Nsa - -
  2 Nsa - -
aP>0.1, thus these were removed from the multivariate regression 
model via backwards selection; bStatistically significant (P<0.05); 
cSmall numbers in variable  and so were ineligible for multivariate 
model analysis. 95% CI, 95% confidence interval; HR, hazard ratio; 
BMI, body‑mass index; ACE‑27, adult  comorbidity evaluation 27 
score; ECOG, eastern cooperative oncology group score; WBC, white 
blood cell count; MPV, mean platelet volume; COP‑MPV, combination 
of platelet count and mean platelet volume score; Ns, not significant.
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